| Literature DB >> 33610274 |
Harald Paganetti1, Clemens Grassberger2, Gregory C Sharp2.
Abstract
The dosimetric advantages of particle therapy lead to significantly reduced integral dose to normal tissues, making it an attractive treatment option for body sites such as the thorax. With reduced normal tissue dose comes the potential for dose escalation, toxicity reduction, or hypofractionation. While proton and heavy ion therapy have been used extensively for NSCLC, there are challenges in planning and delivery compared with X-ray-based radiation therapy. Particularly, range uncertainties compounded by breathing motion have to be considered. This article summarizes the current state of particle therapy for NSCLC with a specific focus on the impact of dosimetric uncertainties in planning and delivery.Entities:
Mesh:
Year: 2021 PMID: 33610274 PMCID: PMC7905707 DOI: 10.1016/j.semradonc.2020.11.004
Source DB: PubMed Journal: Semin Radiat Oncol ISSN: 1053-4296 Impact factor: 5.421